Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Recent studies reported symptomatic overlap between attention deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD). Methylphenidate (MPH) is the most efficient treatment for ADHD. We assessed the efficacy and tolerability of MPH treatment in adolescent females who met the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for both disorders. Fourteen BPD/ADHD female adolescents aged 14-19 years were treated with MPH for 12 weeks, targeting ADHD, BPD symptoms, and aggressive behavior, as rated by ADHD-rating scale (ADHD-RS) and Clinical Global Impression-Severity (CGI-S) scale for BPD and aggressive behavior severity. A significant improvement was detected in both ADHD and BPD severity (baseline vs. end point, ADHD-RS: 33.1+/-4.8 vs. 17.6+/-5.2, P<0.001; BPD CGI-S: 4.6+/-0.8 vs. 3.4+/-0.8, P<0.0005, respectively) as well as in aggressive behavior (Aggression CGI-S: 3.5+/-1.3 vs. 1.8+/-0.5, P<0.001). MPH was well tolerated. MPH may be useful and well tolerated in treating some shared symptoms of ADHD and BPD among female adolescents. Controlled studies are needed to substantiate these findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, individuals presenting with a diagnosis of personality disorder who present with the ADHD syndrome that started in childhood will in many cases benefit from pharmacological treatments for ADHD [232,233].”
From European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD (2010) · cites this paper as [232]
Citations
Cites
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148 · cited 1×
“Psychiatric assessments for comorbidity were made with the Kiddie Schedule for Affective Disorders and Schizophrenia, epidemiologic version (Kiddie-SADS-PL), covering childhood DSM-IV diagnoses (Orvaschel, 1985; Kaufman et al., 1997).”
MethodBARKLEY, R. A., FISCHER, M., EDELBROCK, C. S., & SMALLISH, L. (1990) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199007000-00007 · Cited by 1,507 · cited 1×
“Attention deficit/hyperactivity disorder (ADHD) is the most prevalent neuropsychiatric disorder among children and adolescents, with prevalence rates ranging from 3 to 9% (Barkley et al., 1990; Spencer et al., 1999).”
Background(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.6.885 · Cited by 1,421 · cited 1×
“For this purpose, they used the Wender Utah Rating Scale (WURS), a 61-item scale for assessing adult ADHD that evaluates ADHD-relevant childhood behaviors and symptoms, retrospectively (Ward et al., 1993).”
MethodMethylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder
Aron, A. R., Dowson, J. H., Sahakian, B. J., & Robbins, T. W. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00609-7 · Cited by 391 · cited 1×
“It is possible that the MPH-related improvement in executive function and behavioral inhibition (Aron et al., 2003) is relevant to the beneficial effect in both psychopathologies, despite the differences in core pathophysiology.”
BackgroundATTENTION-DEFICIT/HYPERACTIVITY DISORDER AND COMORBIDITY
Spencer, T., Biederman, J., & Wilens, T. (1999) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70163-2 · Cited by 270 · cited 2×
“Introduction Attention deficit/hyperactivity disorder (ADHD) is the most prevalent neuropsychiatric disorder among children and adolescents, with prevalence rates ranging from 3 to 9% (Barkley et al., 1990; Spencer et al., 1999).”
BackgroundPsychiatric interviews suitable for use in research with children and adolescents.
Orvaschel, H. (1985) · PubMed · Cited by 238
Philipsen, A. (2006) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-006-1006-2 · Cited by 186 · cited 1×
“A number of studies have assessed the relationships between BPD and ADHD, and most of them suggested symptomatic overlap between the two disorders (Dowson et al., 2004; Davids and Gastpar, 2005; Philipsen, 2006).”
BackgroundFossati, A., Novella, L., Donati, D., Donini, M., & Maffei, C. (2002) · Comprehensive Psychiatry · doi:10.1053/comp.2002.34634 · Cited by 182 · cited 1×
“In an attempt to identify the developmental childhood antecedents of BPD and other personality disorders, Fossati et al. (2002) examined the association between the history of childhood ADHD symptoms and diagnosis of BPD in adulthood.”
BackgroundRoss, R. G. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1149 · Cited by 167 · cited 2×
“Despite caution regarding MPH treatment in BPD population, like possible development of addictive behavior for MPH or psychotic deterioration (Ross, 2006; Martin et al., 2007), only one case of psychotic exacerbation in personality disorder patients, treated with MPH, was previously described…”
BackgroundLAMPE, K., KONRAD, K., KROENER, S., FAST, K., KUNERT, H. J., & HERPERTZ, S. C. (2007) · Psychological Medicine · doi:10.1017/s0033291707000517 · Cited by 147 · cited 1×
“Frontocortical-mediated ‘response inhibition’ is a mechanism that may account for the beneficial effects of MPH on both, symptoms of ADHD and BPD, in these adolescent females (Lampe et al. 2007).”
Background
Research works printed but not linked: 2
- Hooberman, 1984, J Clin Psychiatry, 45, 441
- Orvaschel, 1985, Psychopharmacol Bull, 21, 737
Cited by
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928
“Importantly, individuals presenting with a diagnosis of personality disorder who present with the ADHD syndrome that started in childhood will in many cases benefit from pharmacological treatments for ADHD [232,233].”
Top-Down Dysregulation—From ADHD to Emotional Instability
Petrovic, P., & Castellanos, F. X. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00070 · Cited by 179
“…on emotional dysregulation behaviors in ASPD and CD (Kaplan et al., 1990; Brown et al., 1991; Klein et al., 1997; Connor et al., 2000) as well as BPD (Schulz et al., 1988; Golubchik et al., 2008; Prada et al., 2015; although see Schulz et al. (1988) for possible issue with schizotypal comorbidity).”
BackgroundAsherson, P., Young, A. H., Eich-Höchli, D., Moran, P., Porsdal, V., & Deberdt, W. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.915800 · Cited by 130
Matthies, S. D., & Philipsen, A. (2014) · Borderline Personality Disorder and Emotion Dysregulation · doi:10.1186/2051-6673-1-3 · Cited by 110
“A positive effect on self-injurious behavior was observed [95].”
BackgroundWeiner, L., Perroud, N. A., & Weibel, S. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s192871 · Cited by 105
Metadata
- Authors
- Golubchik, P., Sever, J., Zalsman, G., & Weizman, A.
- Affiliations
- Geha Mental Health Center (IL)
- Tel Aviv University (IL)
- Corresponding author
- Golubchik, Pavel
- Venue
- International Clinical Psychopharmacology
- Published
- 2008-07
- Volume
- 23
- Issue
- 4
- Pages
- 228-231
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2034420993
- Cited by
- 36
- References
- 22
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 2 · 2012: 3
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- methylphenidate, attention deficit hyperactivity disorder, borderline personality disorder, adolescent girls, aggression, tolerability
- MeSH terms
- Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Borderline Personality Disorder, Female, Humans, Methylphenidate, Prospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.